Innate Pharma S.A. Statistics
Share Statistics
Innate Pharma S.A. has 82.78M shares outstanding. The number of shares has increased by 0.56% in one year.
| Shares Outstanding | 82.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 31.56M |
| Failed to Deliver (FTD) Shares | 808 |
| FTD / Avg. Volume | 0.34% |
Short Selling Information
The latest short interest is 65.22K, so 0.08% of the outstanding shares have been sold short.
| Short Interest | 65.22K |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.21% |
| Short Ratio (days to cover) | 5.73 |
Valuation Ratios
The PE ratio is -27.85 and the forward PE ratio is 4.22.
| PE Ratio | -27.85 |
| Forward PE | 4.22 |
| PS Ratio | 4.06 |
| Forward PS | 2.4 |
| PB Ratio | 4.06 |
| P/FCF Ratio | -6.04 |
| PEG Ratio | n/a |
Enterprise Valuation
Innate Pharma S.A. has an Enterprise Value (EV) of 173.09M.
| EV / Earnings | -22.87 |
| EV / Sales | 3.33 |
| EV / EBITDA | -94.12 |
| EV / EBIT | -13.66 |
| EV / FCF | -4.96 |
Financial Position
The company has a current ratio of 3.73, with a Debt / Equity ratio of 0.75.
| Current Ratio | 3.73 |
| Quick Ratio | 3.73 |
| Debt / Equity | 0.75 |
| Total Debt / Capitalization | 42.94 |
| Cash Flow / Debt | -0.83 |
| Interest Coverage | -19.8 |
Financial Efficiency
Return on equity (ROE) is -0.15% and return on capital (ROIC) is -13.8%.
| Return on Equity (ROE) | -0.15% |
| Return on Assets (ROA) | -0.04% |
| Return on Capital (ROIC) | -13.8% |
| Revenue Per Employee | 308.93K |
| Profits Per Employee | -45.06K |
| Employee Count | 168 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 26.97% in the last 52 weeks. The beta is 0.87, so Innate Pharma S.A.'s price volatility has been higher than the market average.
| Beta | 0.87 |
| 52-Week Price Change | 26.97% |
| 50-Day Moving Average | 1.8 |
| 200-Day Moving Average | 2.23 |
| Relative Strength Index (RSI) | 45.64 |
| Average Volume (20 Days) | 237.75K |
Income Statement
In the last 12 months, Innate Pharma S.A. had revenue of $51.90M and earned -$7.57M in profits. Earnings per share was $-0.09.
| Revenue | 51.90M |
| Gross Profit | -4.12M |
| Operating Income | -12.67M |
| Net Income | -7.57M |
| EBITDA | -1.84M |
| EBIT | -12.67M |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has $70.61M in cash and $39.89M in debt, giving a net cash position of $30.71M.
| Cash & Cash Equivalents | 70.61M |
| Total Debt | 39.89M |
| Net Cash | 30.71M |
| Retained Earnings | -336.89M |
| Total Assets | 151.50M |
| Working Capital | 73.37M |
Cash Flow
In the last 12 months, operating cash flow was -$32.56M and capital expenditures -$2.35M, giving a free cash flow of -$34.91M.
| Operating Cash Flow | -32.56M |
| Capital Expenditures | -2.35M |
| Free Cash Flow | -34.91M |
| FCF Per Share | -0.43 |
Margins
Gross margin is -7.94%, with operating and profit margins of -24.41% and -14.59%.
| Gross Margin | -7.94% |
| Operating Margin | -24.41% |
| Pretax Margin | -14.59% |
| Profit Margin | -14.59% |
| EBITDA Margin | -3.54% |
| EBIT Margin | -24.41% |
| FCF Margin | -67.26% |
Dividends & Yields
IPHA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.94% |
| FCF Yield | -13.8% |
Analyst Forecast
The average price target for IPHA is $11.5, which is 275.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.5 |
| Price Target Difference | 275.8% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -2.75 |
| Piotroski F-Score | 2 |